Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - quinsair
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp8077ecb6bda7580081b9f65b63060e8a
identifier: http://ema.europa.eu/identifier
/EU/1/14/973/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Quinsair 240 mg nebuliser solution
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-8077ecb6bda7580081b9f65b63060e8a
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/14/973/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - quinsair
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Quinsair contains an antibiotic medicine called levofloxacin. It belongs to the group of antibiotics called fluoroquinolones. Quinsair is used to treat lung infections caused by Pseudomonas aeruginosa in adults with cystic fibrosis. It is an antibiotic medicine that is breathed (inhaled) directly into the lungs where it kills the bacteria causing the infection. This helps to improve breathing in people with cystic fibrosis.
if you have been diagnosed with an enlargement or "bulge" of a large blood vessel (aortic aneurysm or large vessel peripheral aneurysm).
Ciclosporin (used after organ transplants) or medicines that affect your heart beat (such as antiarrhythmics, tricyclic antidepressants, macrolide antibiotics or antipsychotics). Quinsair can interfere with the effects of these medicines. Your doctor will explain more. Pregnancy and breast-feeding Quinsair must not be used whilst pregnant or breast-feeding. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Driving and using machines Quinsair may make you feel dizzy, tired or weak, or cause problems with your eyesight. If this happens to you, do not drive or use any tools or machines.
Do not swallow the liquid in the ampoule. Carefully read the Manufacturer s Instructions for Use, provided with your Zirela Nebuliser Handset. ON Quinsair Use it twice a day for 28 days OFF Quinsair Do not use it for the next 28 days Repeat cycle How do I prepare my Nebuliser System to inhale the medicine? Keep the Zirela Instructions for Use in a safe place as they give full details on assembling the device. 1) Make sure that the Zirela Nebuliser Handset is on a flat and stable surface. 2) Squeeze all of the contents of one ampoule into the medicine reservoir of the Zirela Nebuliser Handset (Figure 1). Ensure that you completely empty the ampoule, gently tapping it against the side of the reservoir if necessary. Figure 1 3) Close the medicine reservoir by aligning the tabs of the medicine cap with the slots of the reservoir (a). Press down and turn the cap clockwise as far as it will go (b, Figure 2). Figure 2 How do I use the Zirela Nebuliser System? 1) When you start your treatment, sit in a relaxed, upright position. 2) Hold the handset level, press and hold the on/off button on the controller for a few seconds. You will hear one beep and the status light will turn green. 3) After a few seconds, an aerosol mist will begin to flow into the aerosol chamber of the Zirela Nebuliser Handset. If aerosol mist does not begin to flow, please refer to the Zirela Manufacturer s Instructions for Use for help. 4) Keeping the handset level, place the mouthpiece in your mouth and close your lips around it (Figure 3). Figure 3 5) Breathe normally (inhale and exhale) through the mouthpiece. Try not to breathe through your nose. Continue to inhale and exhale comfortably until the treatment is finished. It takes about 5 minutes to inhale the medicine using the nebuliser. 6) When all of the medicine has been delivered, you will hear two beeps , which means the treatment is complete. 7) Once complete, open the medicine cap to ensure all of the medicine has been used. A few drops of medicine may remain at the bottom of the reservoir at the end of treatment. This is ok. However if there are more than a few drops left, replace the medicine cap and restart treatment, from step 1. 8) Once treatment is complete, disconnect the controller and take apart the Zirela Nebuliser Handset for cleaning and disinfecting. The Manufacturer s Instructions for Use will give full details on cleaning and disinfecting. What if I need to stop my treatment before I ve finished? If for any reason you must stop the treatment before it's finished, press and hold the controller s on/off button for one second. After it has completely turned itself off and when you are ready to restart, press and hold the on/off button for one second again. Treatment will restart. You must inhale and exhale through the mouthpiece as before. How and when do I replace the Zirela Nebuliser Handset? One nebuliser handset should be used for one 28-day treatment course. Please refer to the Manufacturer s Instructions for Use for cleaning and storage advice. If you use more Quinsair than you should If you have used more Quinsair than you should, tell your doctor as soon as possible. You may experience symptoms like irregular heart beat, which needs to be checked by your doctor. If the contents of the ampoule are swallowed, don t worry but tell your doctor as soon as possible. If you forget to use Quinsair If you forget a dose, use it as soon as you remember as long as there is an 8-hour interval before inhaling the next dose. However if it is nearly the time for your next dose, skip the missed dose. Do not inhale the contents of more than one ampoule to make up for a missed dose. If you stop using Quinsair Do not stop using Quinsair without first talking to your doctor as your lung infection may worsen. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Pain including pain in the back, chest, arms and legs and arms Very rare cases of long lasting (up to months or years) or permanent adverse drug reactions, such as tendon inflammations, tendon rupture, joint pain, pain in the limbs, difficulty in walking, abnormal sensations such as pins and needles, tingling, tickling, burning, depression, fatigue, sleep disorders, memory impairment, as well as impairment of hearing, vision, and taste and smell have been associated with administration of quinolone and fluoroquinolone antibiotics, in some cases irrespective of pre-existing risk factors. Cases of an enlargement and weakening of the aortic wall or a tear in the aortic wall (aneurysms and dissections), which may rupture and may be fatal, and of leaking heart valves have been reported in patients receiving fluoroquinolones. See also section 2. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the ampoule, the foil sachet and the boxes after EXP. The expiry date refers to the last day of that month. Each ampoule is for single use only. Once an ampoule is opened, the contents should be used immediately. Any unused product must be thrown away. Replace any unused, unopened ampoules from the strip back into the sachet to protect them from light. Store in the original package in order to protect from light. This medicine does not require any special temperature storage conditions. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The other ingredients are magnesium chloride hexahydrate and water for injections. What Quinsair looks like and contents of the pack Quinsair is a clear, pale yellow nebuliser solution. The medicine comes in small 3 mL plastic ampoules. Four ampoules are sealed in a foil sachet. Quinsair is supplied as 28-day pack (containing one box of 56 (14 sachets of 4) ampoules) or as 4-day pack (containing 8 (2 sachets of 4) ampoules) and one box holding a Zirela Nebuliser Handset with the Manufacturer s Instructions for Use. Not all pack sizes may be marketed. The ampoule is labelled in English only. The information that appears on the ampoule is: On the front of the ampoule tail Quinsair 240 mg Nebuliser Solution Levofloxacin Inhalation use 2.4 mL In the crimped area on either side of the ampoule tail Lot EXP Marketing Authorisation Holder Chiesi Farmaceutici S.p.A. Via Palermo, 26/A 43122 Parma Italy Manufacturer Adare Pharmaceuticals S.r.l. Via Martin Luther King, 20060 Pessano con Bornago (MI) Italy For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi /Belgique/Belgien Chiesi sa/nv T l/Tel: + 32 (0)2 788 42 Lietuva Chiesi Pharmaceuticals GmbH Tel: + 43 1 4073 Chiesi Bulgaria EOOD Te .: + 359 29201Luxembourg/Luxemburg Chiesi sa/nv T l/Tel: + 32 (0)2 788 42 esk republika Chiesi CZ s.r.o. Tel: + 420 261221Magyarorsz g Chiesi Hungary Kft. Tel.: + 36-1-429 1Danmark Chiesi Pharma AB Tlf: + 46 8 753 35 Malta Chiesi Farmaceutici S.p.A. Tel: + 39 0521 2Deutschland Chiesi GmbH Tel: + 49 40 89724-0 Nederland Chiesi Pharmaceuticals B.V. Tel: + 31 88 501 64 Eesti Chiesi Pharmaceuticals GmbH Tel: + 43 1 4073Norge Chiesi Pharma AB Tlf: + 46 8 753 35
Chiesi Hellas AEBE : + 30 210 6179 sterreich Chiesi Pharmaceuticals GmbH Tel: + 43 1 4073Espa a Chiesi Espa a, S.A.U. Tel: + 34 93 494 8Polska Chiesi Poland Sp. z.o.o. Tel.: + 48 22 620 1France Chiesi S.A.S. T l: + 33 1 47688Portugal Chiesi Farmaceutici S.p.A. Tel: + 39 0521 2Hrvatska Chiesi Pharmaceuticals GmbH Tel: + 43 1 4073Rom nia Chiesi Romania S.R.L. Tel: + 40 212023Ireland Chiesi Farmaceutici S.p.A.
Tel: + 39 0521 2Slovenija Chiesi Slovenija d.o.o. Tel: + 386-1-43 00 sland Chiesi Pharma AB S mi: +46 8 753 35 Slovensk republika Chiesi Slovakia s.r.o. Tel: + 421 259300Italia Chiesi Italia S.p.A. Tel: + 39 0521 2Suomi/Finland Chiesi Pharma AB Puh/Tel: +46 8 753 35
Chiesi Farmaceutici S.p.A. : + 39 0521 2Sverige Chiesi Pharma AB Tel: +46 8 753 35 Latvija Chiesi Pharmaceuticals GmbH Tel: + 43 1 4073United Kingdom (Northern Ireland) Chiesi Farmaceutici S.p.A. Tel: + 39 0521 2This leaflet was last revised in MM/YYYY. Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-8077ecb6bda7580081b9f65b63060e8a
Resource Composition:
Generated Narrative: Composition composition-en-8077ecb6bda7580081b9f65b63060e8a
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/14/973/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - quinsair
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp8077ecb6bda7580081b9f65b63060e8a
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp8077ecb6bda7580081b9f65b63060e8a
identifier:
http://ema.europa.eu/identifier
/EU/1/14/973/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Quinsair 240 mg nebuliser solution
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en